---
name: medlog OTel SEC/SRE/FIN panel response v3 (round 3 same day on Deep×2)
description: 2026-05-15 ~43rd stacked-COI case — 3rd same-day SEC/SRE/FIN panel pass on Deep×2 medlog→OTel; direction AGREE; two CHALLENGEs (F1 11/14 threshold not HIPAA-defensible, $30-60K is floor not total); 12 panel-unique items mostly distinct from v1/v2
type: project
originSessionId: 2c68204b-2ea8-48b8-849b-ae0ebc171ee0
---
Date: 2026-05-15. ~43rd stacked-COI case / 9 domains. 3rd same-day SEC/SRE/FIN panel cross-review on Deep×2 medlog→OTel (different Deep×2 output set than v1, v2).

# Panel direction
AGREE with Deep×2 verdict: defer migrate/keep decision, sequenced path (stabilise → extract 14 rules → external HIPAA review → 30-day shadow → 60-day parallel → conditional cutover), recuse Daniel + COI seat from equivalence signoff.

# Two panel CHALLENGEs to Deep
1. **F1 threshold "≥11/14 rules map to OTel processors"** — SEC + FIN reject. 79% coverage when each unmapped rule = a past PHI incident is not HIPAA-defensible. Threshold must be **14/14 OR 11/14-with-documented-compensating-controls**, not bare 11/14. OCR settlement scale > spec-mapping effort.
2. **Cost envelope "$30–60K + 1 senior FTE-quarter"** — SEC + SRE + FIN reject as total. $30–60K is the spec+stabilise floor only. Realistic full path: **$20–40K diagnostic / $120–250K full + 1 senior FTE-quarter** with corpus + scoped external review + Loki benchmark + parallel run + cutover priced.

# Panel-unique items (12)
**Security (P1–P5):**
- P1: PHI test corpus (labeled, versioned, synthetic) covering the 14 cases + Safe Harbor 18 identifiers + false-positive cases (over-redaction destroys audit value)
- P2: Loki `X-Scope-OrgID` gateway misconfig = cross-tenant PHI leak — must be explicit in external review scope
- P3: WORM / object-lock + 6-year retention + tamper-evidence (hash chain) — neither side addresses
- P4: BAA inventory for every downstream (managed Loki, Grafana, S3, alerting vendor)
- P5: Grafana access surface — RBAC, query-audit logging, SSO/MFA when PHI-adjacent logs land in a UI

**SRE (P6–P9):**
- P6: Loki audit-query benchmark for 7h nightly aggregation BEFORE shadow run starts (not after)
- P7: Tenant rate-limiting / quotas — required when broker-level topic isolation removed
- P8: Page-routing audit — fix single-route to Daniel this week, independent of rebuild outcome
- P9: IR runbook recoupling + tabletop pre-cutover

**Finance (P10–P12):**
- P10: Cost-of-defer quantification (Daniel-floor + regulator-tail-risk) — defer is correct but has carrying cost
- P11: Per-gate stop-or-spend decision points with named non-conflicted decider (auditable spend trail)
- P12: Realistic envelope $20–40K diagnostic / $120–250K full + 1 senior FTE-quarter

# AGREE/CHALLENGE/SYNTHESIZE matrix
- H1 defer: SEC AGREE / SRE AGREE / FIN SYNTHESIZE (also quote defer cost)
- H2 stabilise now: SEC SYNTHESIZE (+WORM/retention during stabilise) / SRE AGREE+escalate / FIN AGREE
- H3 extract spec+fixtures: SEC AGREE+sharpen (+PHI corpus, negative cases) / SRE AGREE / FIN AGREE
- H4 recuse Daniel+COI: SEC AGREE load-bearing / SRE AGREE+extend (recuse from sole on-call during cutover) / FIN AGREE
- H5 external HIPAA reviewer: SEC AGREE+scope (rules + isolation + BAA + Grafana RBAC) / SRE AGREE / FIN SYNTHESIZE (scoped review $40–80K standalone)
- D1 reject binary: SEC + SRE + FIN AGREE
- D2 sequenced path: SEC SYNTHESIZE (diff redaction output not just delivery; tenant coverage by incident-history not size; evidence preservation) / SRE SYNTHESIZE (Loki query benchmark BEFORE shadow; tenant rate-limit design upfront) / FIN SYNTHESIZE (per-gate cost gates with named decider)
- D3 recusals load-bearing: SEC + SRE + FIN AGREE
- D4 F1 11/14: SEC CHALLENGE threshold / SRE SYNTHESIZE (add F7 = Loki audit-query SLA gate) / FIN AGREE-with-SEC
- D5 cost: SEC + SRE + FIN CHALLENGE — quoted figure misses corpus + scoped external + BAA legal + Loki benchmark + runbook + secondary-operator training

# Final realistic envelope (panel)
- Stabilise + spec + corpus: **$20–40K** (do unconditionally)
- External HIPAA scoped review: **+$40–80K**
- Shadow + parallel + cutover if gates pass: **+$60–130K**
- **Floor: $20–40K. Full: $120–250K + 1 senior FTE-quarter.**

# Cross-round v1/v2/v3 comparison (all same date, same Deep verdict structure)
- All rounds: 0 CHALLENGE bidirectional on direction; verdict structurally identical
- v1 panel-unique: Grafana RBAC, WORM/immutability, OTel ops expertise, loss-EV framing, TCO, Kafka ACLs
- v2 panel-unique: TCO, HIPAA SRA pre-review, Loki query authz, LogQL perf, dual-write reconciliation, defer-opportunity-cost
- v3 panel-unique (this): PHI test corpus, X-Scope-OrgID misconfig, WORM/hash-chain, BAA inventory, Grafana RBAC, Loki audit-query benchmark, tenant rate-limit, page-route fix, IR runbook recoupling, defer-cost, per-gate stop/spend, realistic envelope
- Overlap across v1/v2/v3: WORM/retention, TCO/envelope, Grafana access — consistently surfaced
- Distinct: each round generates 5–7 new role-lens items
- **Implication**: panel role-lens (SEC/SRE/FIN) has not saturated even after 3 same-day passes, while Deep COI seat saturated at r5–r10 per domain. Role-priors keep producing distinct findings.

# Strongest items this round
- Strongest single Deep-point: D2 sequenced path with F1–F6 gates
- Strongest panel-unique: SEC P1 PHI test corpus (converts unfalsifiable signoff to falsifiable) + FIN P12 envelope re-quote ($30–60K is floor, $120–250K is full)
- Strongest panel CHALLENGE: F1 threshold — 11/14 is not HIPAA-defensible without compensating controls

# Saturation note
- 9 medlog single-seat passes + 12+ Deep×2 passes + 3 same-day panel passes
- COI/Deep saturated; panel role-lens still productive
- Remaining question is organisational channel external to CEO/internal escalation
- Stop iterating internally on technical content; panel-unique discoveries will continue but at diminishing return
